177Lu-DOTATATE achieves 81.3% disease control in advanced neuroendocrine tumors with acceptable toxicity
Background
Advanced neuroendocrine tumors (NETs) are often aggressive and challenging to treat, with limited curative options once metastatic. These tumors frequently overexpress somatostatin receptors (SSTRs), particularly subtype 2, making them ideal targets for peptide receptor radionuclide therapy (PRRT). Standard systemic therapies can have significant side effects and varying efficacy. 177Lu-DOTATATE leverages this SSTR overexpression, delivering targeted radiation directly to tumor cells while sparing healthy tissue, offering a promising avenue for improved patient outcomes and reduced systemic toxicity.
Study Design
This retrospective study analyzed 49 patients with advanced somatostatin receptor-positive neuroendocrine tumors (NETs) treated with 177Lu-DOTATATE between January 2022 and January 2026. Patients received planned four treatment cycles, with demographic, clinical, imaging, and therapeutic data collected. Treatment response was assessed using RECIST 1.1 criteria, and toxicity was evaluated for hematologic, renal, and hepatic adverse effects. The study aimed to characterize the clinical profile, treatment efficacy, and safety of 177Lu-DOTATATE in a real-world setting.
Results
The study identified pancreatic and small intestine NETs as the most common primary tumors, with liver, lymph node, and bone metastases being the predominant metastatic sites. The majority of individuals successfully completed the planned four treatment cycles. Efficacy data revealed robust disease control: > Disease control was achieved in 81.3% of patients, with partial response observed in 27.1% and stable disease in 54.2% of patients. Toxicity analysis indicated a generally favorable safety profile. Hematologic toxicity was recorded in a minority of eight cases, representing 16.3% of the cohort. Crucially, severe renal or hepatic toxicity remained uncommon, suggesting a manageable side effect profile for 177Lu-DOTATATE in this patient population.
Key Findings
- Disease control was achieved in 81.3% of advanced NETs patients treated with 177Lu-DOTATATE.
- Partial response was observed in 27.1% of patients, and stable disease in 54.2%.
- The majority of 49 patients completed the planned four treatment cycles.
- Hematologic toxicity was recorded in a minority of eight cases (16.3%).
- Severe renal or hepatic toxicity remained uncommon across the cohort.
Why It Matters
This retrospective evaluation reinforces 177Lu-DOTATATE as an effective and generally well-tolerated therapeutic option for patients with advanced neuroendocrine tumors (NETs). The high disease control rates observed, coupled with an acceptable toxicity profile, provide further real-world evidence supporting its use in clinical practice. For clinicians and patients, this means continued confidence in 177Lu-DOTATATE as a robust treatment strategy, especially for those with somatostatin receptor-positive tumors. While specific dosing regimens aren't detailed, the successful completion of "planned four treatment cycles" suggests a standardized, repeatable protocol. This data helps solidify the role of PRRT in the advanced NETs treatment algorithm, potentially guiding future protocol refinements and patient selection.
177lu-dotatate
neuroendocrine-tumors
prrt
somatostatin-receptor
cancer
cohort-study